Sernova Corporation

London, Canada

Sernova Corporation

London, Canada
SEARCH FILTERS
Time filter
Source Type

LONDON, UK / ACCESSWIRE / May 1, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Medical Diagnostics & Research industry. Companies recently under review include Spectral Medical, ProMIS Neurosciences, GeneNews, and Sernova. Get all of our free research reports by signing up at: On Friday, April 28, 2017, at the end of trading session, the Toronto Exchange Composite index ended the day at 15,586.13, 0.51% higher, with a total volume of 323,365,781 shares. The TSX Venture Composite Index, on the other hand, closed at 806.77, up 0.79%. Additionally, the Healthcare index was slightly up by 0.85%, ending the session at 64.11. Active Wall St. has initiated research reports on the following equities: Spectral Medical Inc. (TSX: EDT), ProMIS Neurosciences Inc. (TSX: PMN), GeneNews Ltd. (TSX: GEN), and Sernova Corporation (TSX-V: SVA). Register with us now for your free membership and research reports at: Toronto, Canada headquartered Spectral Medical Inc.'s stock finished Friday's session flat at $0.55 with a total volume of 57,840 shares traded. Over the last one month and the previous three months, Spectral Medical's shares have surged 7.84% and 120.00%, respectively. Shares of the Company shares, which focuses on the development and commercialization of theranostic treatment for septic shock in North America, are trading above its 50-day and 200-day moving averages. Spectral Medical's 50-day moving average of $0.48 is above its 200-day moving average of $0.31. See our research report on EDT.TO at: On Friday, shares in Toronto, Canada headquartered ProMIS Neurosciences Inc. recorded a trading volume of 690,869 shares, which was higher than their three months average volume of 370,663 shares. The stock ended the day 4.84% lower at $0.30. ProMIS Neurosciences' stock has surged 87.50% in the last one month and 76.47% in the previous three months. Furthermore, the stock has rallied 500.00% in the past one year. Shares of the Company, which discovers and develops therapeutics and diagnostics for the treatment of neurodegenerative diseases in Canada, are trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $0.19 is above its 200-day moving average of $0.17. The complimentary research report on PMN.TO at: On Friday, shares in Markham, Canada headquartered GeneNews Ltd. ended the session 3.23% lower at $0.30 with a total volume of 275,000 shares traded. Shares of the Company, which focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications, are trading below its 50-day and 200-day moving averages. Furthermore, the stock's 200-day moving average of $0.39 is greater than its 50-day moving average of $0.37. Register for free and access the latest research report on GEN.TO at: London, Canada headquartered Sernova Corp.'s stock closed the day 15.22% higher at $0.27. The stock recorded a trading volume of 42,100 shares. Sernova's shares have gained 3.85% in the last one month and 8.00% in the past three months. Shares of the company, which engages in the research and development of its proprietary Cell Pouch and associated technologies, including immune-protected therapeutic cells, are trading above their 50-day moving average of $0.26. Get free access to your research report on SVA.V at: Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned


LONDON, UK / ACCESSWIRE / May 1, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Medical Diagnostics & Research industry. Companies recently under review include Spectral Medical, ProMIS Neurosciences, GeneNews, and Sernova. Get all of our free research reports by signing up at: On Friday, April 28, 2017, at the end of trading session, the Toronto Exchange Composite index ended the day at 15,586.13, 0.51% higher, with a total volume of 323,365,781 shares. The TSX Venture Composite Index, on the other hand, closed at 806.77, up 0.79%. Additionally, the Healthcare index was slightly up by 0.85%, ending the session at 64.11. Active Wall St. has initiated research reports on the following equities: Spectral Medical Inc. (TSX: EDT), ProMIS Neurosciences Inc. (TSX: PMN), GeneNews Ltd. (TSX: GEN), and Sernova Corporation (TSX-V: SVA). Register with us now for your free membership and research reports at: Toronto, Canada headquartered Spectral Medical Inc.'s stock finished Friday's session flat at $0.55 with a total volume of 57,840 shares traded. Over the last one month and the previous three months, Spectral Medical's shares have surged 7.84% and 120.00%, respectively. Shares of the Company shares, which focuses on the development and commercialization of theranostic treatment for septic shock in North America, are trading above its 50-day and 200-day moving averages. Spectral Medical's 50-day moving average of $0.48 is above its 200-day moving average of $0.31. See our research report on EDT.TO at: On Friday, shares in Toronto, Canada headquartered ProMIS Neurosciences Inc. recorded a trading volume of 690,869 shares, which was higher than their three months average volume of 370,663 shares. The stock ended the day 4.84% lower at $0.30. ProMIS Neurosciences' stock has surged 87.50% in the last one month and 76.47% in the previous three months. Furthermore, the stock has rallied 500.00% in the past one year. Shares of the Company, which discovers and develops therapeutics and diagnostics for the treatment of neurodegenerative diseases in Canada, are trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $0.19 is above its 200-day moving average of $0.17. The complimentary research report on PMN.TO at: On Friday, shares in Markham, Canada headquartered GeneNews Ltd. ended the session 3.23% lower at $0.30 with a total volume of 275,000 shares traded. Shares of the Company, which focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications, are trading below its 50-day and 200-day moving averages. Furthermore, the stock's 200-day moving average of $0.39 is greater than its 50-day moving average of $0.37. Register for free and access the latest research report on GEN.TO at: London, Canada headquartered Sernova Corp.'s stock closed the day 15.22% higher at $0.27. The stock recorded a trading volume of 42,100 shares. Sernova's shares have gained 3.85% in the last one month and 8.00% in the past three months. Shares of the company, which engages in the research and development of its proprietary Cell Pouch and associated technologies, including immune-protected therapeutic cells, are trading above their 50-day moving average of $0.26. Get free access to your research report on SVA.V at: Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned LONDON, UK / ACCESSWIRE / May 1, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Medical Diagnostics & Research industry. Companies recently under review include Spectral Medical, ProMIS Neurosciences, GeneNews, and Sernova. Get all of our free research reports by signing up at: On Friday, April 28, 2017, at the end of trading session, the Toronto Exchange Composite index ended the day at 15,586.13, 0.51% higher, with a total volume of 323,365,781 shares. The TSX Venture Composite Index, on the other hand, closed at 806.77, up 0.79%. Additionally, the Healthcare index was slightly up by 0.85%, ending the session at 64.11. Active Wall St. has initiated research reports on the following equities: Spectral Medical Inc. (TSX: EDT), ProMIS Neurosciences Inc. (TSX: PMN), GeneNews Ltd. (TSX: GEN), and Sernova Corporation (TSX-V: SVA). Register with us now for your free membership and research reports at: Toronto, Canada headquartered Spectral Medical Inc.'s stock finished Friday's session flat at $0.55 with a total volume of 57,840 shares traded. Over the last one month and the previous three months, Spectral Medical's shares have surged 7.84% and 120.00%, respectively. Shares of the Company shares, which focuses on the development and commercialization of theranostic treatment for septic shock in North America, are trading above its 50-day and 200-day moving averages. Spectral Medical's 50-day moving average of $0.48 is above its 200-day moving average of $0.31. See our research report on EDT.TO at: On Friday, shares in Toronto, Canada headquartered ProMIS Neurosciences Inc. recorded a trading volume of 690,869 shares, which was higher than their three months average volume of 370,663 shares. The stock ended the day 4.84% lower at $0.30. ProMIS Neurosciences' stock has surged 87.50% in the last one month and 76.47% in the previous three months. Furthermore, the stock has rallied 500.00% in the past one year. Shares of the Company, which discovers and develops therapeutics and diagnostics for the treatment of neurodegenerative diseases in Canada, are trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $0.19 is above its 200-day moving average of $0.17. The complimentary research report on PMN.TO at: On Friday, shares in Markham, Canada headquartered GeneNews Ltd. ended the session 3.23% lower at $0.30 with a total volume of 275,000 shares traded. Shares of the Company, which focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications, are trading below its 50-day and 200-day moving averages. Furthermore, the stock's 200-day moving average of $0.39 is greater than its 50-day moving average of $0.37. Register for free and access the latest research report on GEN.TO at: London, Canada headquartered Sernova Corp.'s stock closed the day 15.22% higher at $0.27. The stock recorded a trading volume of 42,100 shares. Sernova's shares have gained 3.85% in the last one month and 8.00% in the past three months. Shares of the company, which engages in the research and development of its proprietary Cell Pouch and associated technologies, including immune-protected therapeutic cells, are trading above their 50-day moving average of $0.26. Get free access to your research report on SVA.V at: Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-16-2015 | Award Amount: 5.56M | Year: 2015

The main objective of the HemAcure project is to develop and refine the tools and technologies for a novel ex vivo prepared cell based therapy to treat the bleeding disease haemophilia A (caused by genetic deficiency in clotting factor VIII (FVIII)) that should ultimately lead to improved quality of life of the patients. The concept is a further development of our approach, established during the FP7 ReLiver project led by Medicyte. From the very beginning, we balance two important goals, maximizing the products efficacy and safety profile on one side and minimizing production cost on the other by enhancing the products manufacturability. HemAcure relates to the work program as we focus on the refinement of all steps and tools of our ex vivo gene therapy approach. These steps involve 1) isolation and culture of cells from patients blood, 2) manipulation of patient cells to repair its genetic defect by ex vivo introducing the correct genetic copy of FVIII (mutations in this gene lead to hemophilia A), 3) automation of cell expansion in a novel and passage-less scalable bioreactor, 4) continuously monitoring of cells during and after expansion with respect to their safety profile and functionality, 5) cell implantation into a worldwide unique medical device for targeted delivery of therapeutic Factor VIII and 6) proof-of-concept and safety studies in appropriate haemophilia A animal models. The aim of adapting the proof-of-concept to GMP requires a risk based approach, by means of a clear understanding of the whole process from design to production of the therapeutic cells and a systematic way to identify and prevent risks that are not acceptable for the patient. All steps will be designed and conducted according to European GMP-regulations to ensure that the product will fully comply to the requirements for quality of the European authorities.


Pepper A.R.,University of Western Ontario | Pepper A.R.,Sernova Corporation | Welch I.,University of Western Ontario | Bruni A.,Sernova Corporation | And 4 more authors.
Pancreas | Year: 2013

OBJECTIVE: A stringent porcine islet autograft diabetes model was developed to enable the assessment of autoislet safety and efficacy in either portal vein or an extrahepatic site. METHODS: A 95% pancreatectomy was performed preserving the pancreaticoduodenal arcade; however, glycemic control was still maintained at 3.3 ± 0.3 days (mean ± SEM), shown by euglycemic fasting blood glucose levels of 4.9 ± 0.8 mmol/L (mean ± SEM, n = 3). To reduce surgical complications and eliminate remaining islets, pigs were dosed intravenously after a modified 90% pancreatectomy, with 150-mg/kg streptozotocin, producing a diabetic state (18.9 ± 1.8 mmol/L [mean ± SEM], n = 8; P < 0.001) within 2.0 ± 0.9 days (mean ± SEM). RESULTS: Animals presented with sustained hyperglycemia, failing a glucose challenge test 12 weeks after diabetic induction, and showed no stimulated C-peptide secretion compared to nondiabetic controls (baseline: 0.479 ± 0.080 ng/mL [mean ± SEM] vs after procedure: 0.219 ± 0.055 ng/mL [mean ± SEM], P = 0.02). Diabetic animals were maintained on daily insulin. Despite an initial decline in body weight acutely after pancreatectomy and streptozotocin administration, the mean body weight increased after induction over the approximately 88-day study, indicating that the animals were in good health. CONCLUSION: This stringent porcine model of diabetic induction should be used to assess autograft transplantation safety and efficacy. Copyright © 2013 Lippincott Williams & Wilkins.


Kriz J.,University of Western Ontario | Vilk G.,University of Western Ontario | Vilk G.,London Health Sciences Center | Vilk G.,Sernova Corporation | And 8 more authors.
American Journal of Surgery | Year: 2012

Background: The greater omentum with its vascularization and blood flow has been considered as a location for islet transplantation; however, there is a need to provide a controlled and protected site for the islets within the omentum that would be applicable to donor islets and future stem cell technologies. Here we describe the use of a novel device implanted within the omentum with a subcutaneous delivery port that offers an environment for donor islets. Methods: A prototype cell pouch device was wrapped in the greater omentum and an islet implantation port was exposed subcutaneously in diabetic Lewis rats. After tissue growth throughout the device, islet isografts were implanted and long-term glucose control was evaluated. Results: By using this technique, 7 of 10 diabetic rat recipients showed long-term normal blood glucose levels after minimal islet dose transplants. Histologic assessment revealed collagen formation and vascularization within the device. Conclusions: The implanted device assessed using this technique provides a safe and efficacious environment for the support of pancreatic islets contained within a removable device as a cell therapy in a highly vascularized setting. © 2012 Elsevier Inc. All rights reserved.


Pepper A.R.,University of Alberta | Pawlick R.,University of Alberta | Gala-Lopez B.,University of Alberta | MacGillivary A.,Sernova Corporation | And 4 more authors.
Transplantation | Year: 2015

Background. Islet transplantation is a successful â-cell replacement therapy for selected patients with type 1 diabetes mellitus. Although high rates of early insulin independence are achieved routinely, long-termfunction wanes over time. Intraportal transplantation is associated with procedural risks, requiresmultiple donors, and does not afford routine biopsy. Stem cell technologiesmay require potential for retrievability, and graft removal by hepatectomy is impractical. There is a clear clinical need for an alternative, optimized transplantation site. The subcutaneous space is a potential substitute, but transplantation of islets into this site has routinely failed to reverse diabetes. However, an implanted device, which becomes prevascularized before transplantation, may alter this equation.Methods. Syngeneic mouse islets were transplanted subcutaneously within Sernova Corp's Cell Pouch (CP). All recipients were preimplanted with CPs 4 weeks before diabetes induction and transplantation. After transplantation, recipients were monitored for glycemic control and glucose tolerance. Results. Mouse islets transplanted into the CP routinely restored glycemic control with modest delay and responded well to glucose challenge, comparable to renal subcapsular islet grafts, despite a marginal islet dose, and normoglycemia was maintained until graft explantation. In contrast, islets transplanted subcutaneously alone failed to engraft. Islets within CPs stained positively for insulin, glucagon, and microvessels. Conclusions. The CP is biocompatible, forms an environment suitable for islet engraftment, and offers a potential alternative to the intraportal site for islet and future stem cell therapies. © 2015 Wolters Kluwer Health, Inc. All rights reserved.


Patent
Sernova Corporation | Date: 2015-02-18

Devices and methods for transplanting cells in a host body are described. The cell comprises a porous scaffold that allows ingrowth of vascular and connective tissues, a plug or plug system configured for placement within the porous scaffold, and a seal configured to enclose a proximal opening in the porous scaffold. The device may further comprise a cell delivery device for delivering cells into the porous scaffold. The method of cell transplantation comprises a two step process. The device is incubated in the host body to form a vascularized collagen matrix around a plug positioned within the porous scaffold. The plug is then retracted from the porous scaffold, and cells are delivered into the vascularized space created within the porous scaffold.


Patent
Sernova Corporation | Date: 2016-01-12

Devices and methods for transplanting cells in a host body are described. The cell comprises a porous scaffold that allows ingrowth of vascular and connective tissues, a plug or plug system configured for placement within the porous scaffold, and a seal configured to enclose a proximal opening in the porous scaffold. The device may further comprise a cell delivery device for delivering cells into the porous scaffold. The method of cell transplantation comprises a two step process. The device is incubated in the host body to form a vascularized collagen matrix around a plug positioned within the porous scaffold. The plug is then retracted from the porous scaffold, and cells are delivered into the vascularized space created within the porous scaffold.

Loading Sernova Corporation collaborators
Loading Sernova Corporation collaborators